Avenue therapeutics announces high potency and full efficacy in a model of generalized seizures for its novel gaba-a receptor potentiator, baer-101, supporting phase 2 clinical study

-a phase 2a study of baer-101 in epilepsy is planned to initiate in 2024 -a phase 2a study of baer-101 in epilepsy is planned to initiate in 2024

ATXI Ratings Summary

ATXI Quant Ranking